Health & Environmental Research Online (HERO)


Print Feedback Export to File
7043829 
Journal Article 
Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects 
Park, DB; Jang, K; Lee, JW; Park, CW; Lee, BH; Kim, MG; Jeon, JY; , 
2017 
Yes 
International Journal of Clinical Pharmacology and Therapeutics
ISSN: 0946-1965 
DUSTRI-VERLAG DR KARL FEISTLE 
DEISENHOFEN-MUENCHEN 
286-294 
English 
28079517 
WOS:000397939800012 
A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to enhance patient compliance. 
• PFAS Universe
     Data Source
          Web of Science
          Screened Studies
               Excluded
                    Exclude (TIAB)
     Perflunafene